About: Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening
Creator	Liu, Chang Zhao, Yang Feng, Xiaoling Jiang, Yuepeng Qu, Fan Xi, Hongyan Zhao, Xiaoxuan
Source	Medline; PMC
abstract	To analyze the susceptibility of SARS-CoV-2 in pregnancy and the drugs that can be used to treat pregnancy with COVID-19, so as to provide evidence for drug selection in clinic. By reviewing the existing literature, this paper analyzes the susceptibility of pregnant women to virus, especially to SARS-CoV-2, from the aspects of anatomical, reproductive endocrine and immune changes during pregnancy and screens effective and fetal-safe treatments from the existing drugs. The anatomical structure of the respiratory system is changed during pregnancy, and the virus transmitted by droplets and aerosols is more easily inhaled by pregnant women and is difficult to remove. Furthermore, the prognosis is worse after infection when compared with non-pregnancy women. And changes in reproductive hormones and immune systems during pregnancy collectively make them more susceptible to certain infections. More importantly, angiotensin-converting enzyme (ACE)-2, the SARS-CoV-2 receptor, has been proven highly increased during pregnancy, which may contribute to the susceptibility to SARS-CoV-2. When it comes to treatment, specific drugs for COVID-19 have not been found at present, and taking old drugs for new use in treating COVID-19 has become an emergency method for the pandemic. Particularly, drugs that show superior maternal and fetal safety are worthy of consideration for pregnant women with COVID-19, such as chloroquine, metformin, statins, lobinavir/ritonavir, glycyrrhizic acid, and nanoparticle-mediated drug delivery (NMDD), etc. Pregnant women are susceptible to COVID-19, and special attention should be paid to the selection of drugs that are both effective for maternal diseases and friendly to the fetus. However, there are still many deficiencies in the study of drug safety during pregnancy, and broad-spectrum, effective and fetal-safe drugs for pregnant women need to be developed so as to cope with more infectious diseases in the future.
has issue date	2020-04-23(xsd:dateTime)
bibo:doi	10.1007/s10096-020-03897-6
bibo:pmid	32328850
has license	no-cc
sha1sum (hex)	4d18b1c195fd0e9bf990f0fc4e9af0ac8c64ed69
schema:url	https://doi.org/10.1007/s10096-020-03897-6
resource representing a document's title	Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening
has PubMed Central identifier	PMC7178925
has PubMed identifier	32328850
schema:publication	Eur J Clin Microbiol Infect Dis
resource representing a document's body	covid:4d18b1c195fd0e9bf990f0fc4e9af0ac8c64ed69#body_text
is schema:about of	named entity 'pandemic' named entity 'drugs' named entity 'susceptible' named entity 'drugs' named entity 'angiotensin-converting enzyme' covid:arg/4d18b1c195fd0e9bf990f0fc4e9af0ac8c64ed69 named entity 'paper' named entity 'consideration' named entity 'receptor' named entity 'anatomical' named entity 'droplets' named entity 'And' named entity 'highly' named entity 'susceptibility' named entity 'drugs' named entity 'study' named entity 'COVID-19' named entity 'superior' named entity 'maternal' named entity 'drugs' named entity 'susceptibility' named entity 'respiratory system' named entity 'COVID-19' named entity 'proven' named entity 'susceptibility' named entity 'COVID' named entity 'infectious diseases' named entity 'pregnant women' named entity 'ritonavir' named entity 'pregnant women' named entity 'pregnancy' named entity 'pregnancy' named entity 'endocrine' named entity 'statins' named entity 'prognosis' named entity 'SARS-CoV-2' named entity 'nanoparticle' named entity 'anatomical structure' named entity 'SARS-CoV-2' named entity 'pregnancy' named entity 'aerosols' named entity 'fetal' named entity 'fetus' named entity 'SARS-CoV-2' named entity 'Vero E6' named entity 'infectious diseases' named entity 'glucose' named entity 'virus' named entity 'Coronaviridae' named entity 'virus' named entity 'infection' named entity 'glucose' named entity 'CMV' named entity 'host-directed' named entity 'Columbia University' named entity 'amino acids' named entity 'IFN' named entity 'Chloroquine phosphate' named entity 'IFN-α' named entity 'higher risk' named entity 'fetus' named entity 'miscarriages' named entity 'kidney cells' named entity 'antiviral therapy' named entity 'COVID' named entity 'COVID' named entity 'pregnant women' named entity 'cytokine secretion' named entity 'teratogenicity' named entity 'homology model' named entity 'trimester of pregnancy' named entity 'progesterone' named entity 'lovastatin' named entity 'spike (S) protein' named entity 'vaccines'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software